Averna Therapeutics Overview
Averna Therapeutics is a biotechnology company specializing in the development of genomic medicines aimed at treating a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's proprietary technology focuses on inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome. These regions are selected to allow stable gene integration without disrupting normal cellular functions. By encoding their medicines in RNA, Averna utilizes validated, non-viral delivery platforms that are designed to be safe, efficient, scalable, and cost-effective. This approach also permits redosing with the intent to achieve curative outcomes.
Cumulative Funding Raised Over Time ($)
$82.0MJun 2024
Latest News
growth-positive
The former Moderna CMO, who led development of the company's Covid vaccine, tells "Globes" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.
Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A financing round. The company is led by Dr. Tal Zaks, former chief medical officer at Moderna, and is developing a novel approach to gene editing using mRNA technology to treat rare genetic diseases. The company aims to move to the preclinical trial stage with its technology, which has garnered interest due to its potential to treat a variety of diseases, including cancer and autoimmune disorders. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas approach.
InvestmentProduct Stage
growth-positive
Tal Zaks's Israeli startup targets rare genetic diseases
Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A round. The company is led by Dr. Tal Zaks, former CMO of Moderna, and is developing a new approach to gene editing using mRNA technology. The company aims to treat rare genetic diseases and potentially develop drugs for cancer and autoimmune diseases. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas potential. The company is in the preclinical trial stage and plans to keep research in Israel while sharing development with the US.
InvestmentManagement ChangesProduct Stage
growth-positive
Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Exsilio Therapeutics, a biotechnology company developing genomic medicines, has emerged from stealth with $82 million in Series A financing. The funding round was co-led by Novartis Venture Fund and Delos Capital, with participation from several other investors. Exsilio focuses on creating genomic medicines that use mRNA and lipid nanoparticles to insert genes into safe harbor sites in the human genome. The company aims to treat genetic diseases, cancer, and autoimmune conditions with medicines that can be redosed and titrated. The investment will help Exsilio advance its genomic medicines and select promising lead candidates.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $82M |
| Last funding | $82M |
| Stage | A |
| Rounds | 1 |
| Investors | 10 |
Team Members
3
Employees: 51-200
Web & Social Links
| Website | avernatx.com/ |
Locations
Ilan Ramon St, Ness Ziona, Israel
Photos & Videos
No files yet
Averna Therapeutics Business
Business models
B2B, B2C
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsGenesTags (2)
pharmaceuticalshealthcareAverna Therapeutics Financials
$82M
Total funding
Undisclosed
Capital raised
$82M
Last funding
A
Funding stage
1
Total rounds
10
Investors
Cumulative Funding Raised Over Time ($)
$82.0MJun 2024
Private Equity Funding
A Round
Jun 2024
$82M
Delos Capital (Lead), Novartis Venture Fund (Lead)
,
Insight Partners, CRISPR Therapeutics, JPMorgan Chase & Co, Deep Insight, OrbiMed, Innovation Endeavors, Arc Ventures, Invus
Averna Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$82.0MJun 2024
All Events
A Round
Jun 2024
$82M
Delos Capital (Lead), Novartis Venture Fund (Lead)
,
Insight Partners, CRISPR Therapeutics, JPMorgan Chase & Co, Deep Insight, OrbiMed, Innovation Endeavors, Arc Ventures, Invus
Averna Therapeutics News
3 articles
growth-positive
The former Moderna CMO, who led development of the company's Covid vaccine, tells "Globes" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.
Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A financing round. The company is led by Dr. Tal Zaks, former chief medical officer at Moderna, and is developing a novel approach to gene editing using mRNA technology to treat rare genetic diseases. The company aims to move to the preclinical trial stage with its technology, which has garnered interest due to its potential to treat a variety of diseases, including cancer and autoimmune disorders. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas approach.
InvestmentProduct Stage
growth-positive
Tal Zaks's Israeli startup targets rare genetic diseases
Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A round. The company is led by Dr. Tal Zaks, former CMO of Moderna, and is developing a new approach to gene editing using mRNA technology. The company aims to treat rare genetic diseases and potentially develop drugs for cancer and autoimmune diseases. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas potential. The company is in the preclinical trial stage and plans to keep research in Israel while sharing development with the US.
InvestmentManagement ChangesProduct Stage
growth-positive
Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Exsilio Therapeutics, a biotechnology company developing genomic medicines, has emerged from stealth with $82 million in Series A financing. The funding round was co-led by Novartis Venture Fund and Delos Capital, with participation from several other investors. Exsilio focuses on creating genomic medicines that use mRNA and lipid nanoparticles to insert genes into safe harbor sites in the human genome. The company aims to treat genetic diseases, cancer, and autoimmune conditions with medicines that can be redosed and titrated. The investment will help Exsilio advance its genomic medicines and select promising lead candidates.
Investment
Averna Therapeutics Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 51 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Averna Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 72/100 |
| Missing | sector, tags, video or image, markets, not claimed |
| Registrar ID | 516545126 |
| Crunchbase | exsilio-therapeutics |
| Creator | Ido Kilberg |
| Creator email | ido@deepinsight.co.il |
| Last updater | Jenny Sotnik-Talisman |
| Updater email | jenny.sotnik@sncentral.org |
| Last update | 2025-01-30T00:00:00.000Z |
| Created | 2024-09-16T00:00:00.000Z |